Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 80

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 1
Chunk 80
---
 30,Geographic Regions2025202420252024U.S.$3,294 $2,593 $9,479 $7,317 Europe, Middle East and Africa793 773 2,518 2,398 Asia-Pacific802 684 2,292 2,002 Latin America and Canada175 159 499 469 Total Net Sales$5,065 $4,209 $14,788 $12,186 Emerging Markets(1)$765 $684 $2,214 $2,012 (1) Our Emerging Markets countries include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada.Deferred RevenueContract liabilities are classified within Other current liabilities and Other long-term liabilities within our accompanying unaudited consolidated balance sheets. Our deferred revenue balance was $668 million as of September 30, 2025 and $635 million as of December 31, 2024. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiology business, for which revenue is recognized over the average service period based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our Cardiology business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $65 million in the third quarter and $201 million in the first nine months of 2025 that was included in the above contract liability balance as of December 31, 2024. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred. Variable Consideration

For additional information on variable consideration, refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K. 

37

Table of Contents

NOTE L – CHANGES IN OTHER COMPREHENSIVE INCOMEThe following tables provide the reclassifications out of Other comprehensive income (loss), net of tax attributable to Boston Scientific common stockholders: (in millions)Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotalBalance as of June